DuPont Introduces Higher-Adhesion, Low-Cyclics Silicone Soft Skin Adhesive
Recently, DuPont announced the launch of new DuPont™ Liveo™ MG 7-9960 soft skin adhesive. The higher-adhesion, low-cyclics silicone soft skin adhesive (SSA) is designed for use in advanced wound care dressings and for adhering medical devices to the skin for long-term wear and gentle removal.
DuPont™ Liveo™, a globally recognized leader in silicone technology for medical devices, defines the critical quality attributes of silicone skin adhesives. These technologies are already widely used in the advanced wound care and scar treatment markets, and now DuPont will further strengthen its existing product series with this new SSA solution.
New DuPont™ Liveo™ MG 7-9960 soft skin adhesive has the highest peel adhesion of the Liveo™ SSA family, enabling better fit, painless removal, re-application, and improved durability Wear resistance and design flexibility. In addition, low-ring Liveo™ MG 7-9960 SSA is non-allergenic, non-irritating and non-cytotoxic, making it ideal for protecting sensitive and fragile skin of children, the elderly and patients with dermatological diseases or open wounds.
DuPont developed this adhesive as part of its efforts to expand its portfolio of solutions to support the growing medical device market. The adhesive also enables manufacturers to fine-tune performance to meet the application requirements of medical device designers by adjusting coating weight.
"As difficult-to-heal wounds become more common and wound healing rates need to improve, we are looking to expand our portfolio of medical-grade adhesive solutions and work with medical device OEMs and processors to support their development of new dressings or Wearable design." said Jennifer Gemo, global strategic marketing leader for DuPont™ Liveo™ Healthcare Solutions.
"Because customers have unique medical device designs and processes, it is critical not only to supply high-quality, high-performance materials but also to support customers in optimizing their product development," Said Audrey Wipret, technical services and development specialist and medical device expert of DuPont™ Liveo™ Healthcare Solutions in Europe, the Middle East and Africa.
2026-10-11
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Mitsubishi Chemical to Halt Production of Key Epoxy Resin Grades by 2027
-
Evonik Inaugurates New Speciality Alumina Plant in Japan, Bolstering Regional Growth Strategy
-
Brazil’s SISPA Platform Signals a New Phase in Pesticide Registration
-
Braskem to Expand Ethylene and Polyethylene Production Capacity
-
Zydus Brings the First Keytruda Biosimilar Showdown to North America
-
BASF’s 2025 Report Card—“The Profit Evaporation Act”: Behind the €6.6 Billion EBITDA Lies a Deliberate Strategic Retreat
-
Dow Q3 2025: Struggling at the Bottom of the Cycle Amid a Slow Structural Recovery
-
BASF Personal Care Launches Ameriflor Calm
-
Brenntag and Momentive Expand Partnership to the Philippines
-
Asahi Kasei Draws the Line on HMD: Strategic Exit from Hexamethylenediamine Production Signals Portfolio Refocus
Recommend Reading
-
Wanhua Chemical’s “Tale of Two Cities”: 850,000 Tonnes Isn’t Capacity—It’s a Declaration of War
-
AkzoNobel Completes Sale of AkzoNobel India Limited to JSW Group
-
“Fluoro-Fiasco”? Sudden Full Shutdown of Huayi Group’s Fluorochemical Plant Sends Shockwaves Through PVDF Markets
-
Celanese Sells 19% Nutrinova Stake for $152 Million; Mitsui & Co. Raises Holding to 89% to Complete Upstream Integration
-
Sichuan’s 120,000 Tons Approved, Shandong’s 500,000 Tons on the Way:Is Wanhua Chemical Set to “Break Through” the LFP Market?
-
Your Plant Has the Data. Your AI Cannot Reach It. Here Is Why That Is the Core Problem in Chemical Manufacturing.
-
FDA Dye Pledges Push Natural Colors Into the Mainstream
-
Business Society September 18, 2026 Lithium Carbonate Trend Analysis: Strong Rebound
-
Business Society’s September 18, 2026 Caustic Soda Trend Analysis: Relatively Strong Fluctuations
-
FDA Fee Updates Raise the Cost of Entering the U.S. Generic Drug Chain